DexCom IncDXCM
▲ PositiveCapitalrelevance
Piper Sandler raised price target to $88 and TD Cowen to $95, both maintaining positive ratings, citing pipeline visibility and FDA clearance.
Impact on stocks 1
Biotech & Genomic Medicine
DexCom IncPiper Sandler analyst Matt O'Brien raised the firm's price target on DexCom to $88 from $75 while maintaining an Overweight rating, citing greater visibility into the long-term pipeline and catalyst cadence supporting sustained, outsized top-line growth. The move follows the U.S. Food and Drug Administration's clearance of DexCom's Stelo Glucose Biosensor System as the first over-the-counter continuous glucose monitor for children aged two and older who do not use insulin, expanding on the March 2024 clearance for adults. Earlier in the week, TD Cowen analyst Joshua Jennings also raised his price target on DexCom to $95 from $75 with a Buy rating, highlighting the company's position in the T2NIT coverage expansion initiative and the compelling CONNECT dataset for payers.
DexCom IncPiper Sandler raised price target to $88 and TD Cowen to $95, both maintaining positive ratings, citing pipeline visibility and FDA clearance.